Ruxolitinib [941678-49-5]
Referentie HY-50856-1ml
Formaat : 10mM/1mL
Merk : MedChemExpress
Ruxolitinib (INCB18424) est un inhibiteur de JAK1/2 qui est puissant et sélectif avec des IC50s de 3,3 nM et 2,8 nM dans les tests sans cellules, et a une sélectivité de 130 fois pour JAK1/2 sur JAK3. Ruxolitinib induit l'autophagie et tue les cellules tumorales par une mitophagie toxique.
Ruxolitinib (INCB18424) ist ein potenter und selektiver JAK1/2-Inhibitor mit IC50s von 3,3 nM und 2,8 nM in zellfreien Assays und hat eine 130-fache Selektivität für JAK1/2 gegenüber JAK3. Ruxolitinib induziert autophagy und tötet Tumorzellen durch toxische mitophagy ab.
Ruxolitinib (INCB18424) is an orally active and selective JAK1/2 inhibitor with IC50s of 3.3 nM and 2.8 nM in cell-free assays, and has 130-fold selectivity for JAK1/2 over JAK3. Ruxolitinib induces autophagy and kills tumor cells through toxic mitophagy.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
Ruxolitinib Chemical Structure
CAS No. : 941678-49-5
This product is a controlled substance and not for sale in your territory.
Based on 160 publication(s) in Google Scholar
Other Forms of Ruxolitinib:
- Ruxolitinib (S enantiomer) In-stock
- Ruxolitinib phosphate In-stock
- Deuruxolitinib Obtenir un devis
- (Rac)-Ruxolitinib-d9 Obtenir un devis
- Ruxolitinib sulfate Obtenir un devis
- Ruxolitinib (Standard) Obtenir un devis
-
Ruxolitinib purchased from MedChemExpress. Usage Cited in: Nature. 2022 Sep;609(7928):785-792. [Abstract]
- Huh7 cells are pretreated with DMSO, 5 μM Filgotinib, 5 μM Ruxolitinib or 5 μM IFNα-IFNAR-IN-1 hydrochloride for 1 h and infected with MERS-CoV at a MOI of 1. MERS-CoV N gene copy number is quantified by RT-qPCR.
-
Ruxolitinib purchased from MedChemExpress. Usage Cited in: Cell Mol Immunol. 2022 Oct;19(10):1130-1140. [Abstract]
- The expression of phosphorylated (p-) and unphosphorylated STAT1 and STAT6 in macrophages is assessed by western blotting.
-
Ruxolitinib purchased from MedChemExpress. Usage Cited in: Cell Mol Immunol. 2022 Oct;19(10):1130-1140. [Abstract]
- Ruxolitinib (100 mg/kg/day; intraperitoneal injection; 8 weeks) reduces the expression of proinflammatory cytokine genes in the livers of ARE-Del+/− mice. RNA is isolated from the livers of Ruxolitinib-treated mice.
-
Ruxolitinib purchased from MedChemExpress. Usage Cited in: Cell Mol Immunol. 2022 Oct;19(10):1130-1140. [Abstract]
- Levels of IL-6, TNF, and MCP1 production in macrophages isolated from wild-type mice (females/20 weeks) following in vitro treatment with Ruxolitinib are determined utilizing CBA and flow cytometry.
-
Ruxolitinib purchased from MedChemExpress. Usage Cited in: Nat Cancer. 2022 Sep;3(9):1071-1087. [Abstract]
- Relative cell number of LNCaP/AR cells treated with annotated treatment: 10 µM Enzalutamide (Enz), 5 µM Filgotinib (Filg), 5 µM Ruxolitinib (Ruxo), 1 µM Fludarabine (Flu), 0.2 µM Niclosamide (Nic) and DMSO for 8 days.
-
Ruxolitinib purchased from MedChemExpress. Usage Cited in: Theranostics. 2022 Oct 3;12(16):7051-7066.
- A549 cells are treated with 2.5 µM BVD and 10 µM Ruxolitinib (Rux) separately or in combination for 2 days. Immunoblotting is conducted to determine pSTAT3-Y705.
-
Ruxolitinib purchased from MedChemExpress. Usage Cited in: Proc Natl Acad Sci U S A. 2022 Apr 12;119(15):e2122512119. [Abstract]
- Representative DDX4 immunofluorescence following 48 h incubation of ovaries from PND2 mice cultured ex vivo with 1 μM candidate MISR2 agonists Gandotinib, SP600125, CYC-116, Ruxolitinib.
-
Ruxolitinib purchased from MedChemExpress. Usage Cited in: Proc Natl Acad Sci U S A. 2022 Apr 12;119(15):e2122512119. [Abstract]
- The induction of MIS target genes Id2, Id3, Smad6, and Igfbp5 was recapitulated as measured by qPCR following a 48 h incubation of ex vivo cultured ovaries from PND2 rat with 1 μM candidate MISR2 agonists Gandotinib, SP600125m, CYC-116, Ruxolitinib.
-
Ruxolitinib purchased from MedChemExpress. Usage Cited in: Cell Death Dis. 2022 May 25;13(5):496. [Abstract]
- The xenografts treated with both Trametinib and Ruxolitinib (20 mg/kg; i.p.; every 3 days) show the expression of pSTAT3 and pERK1/2 in xenograft tumors exposed to the indicated treatment. Densitometry analyses of pSTAT3 and pERK1/2 expression normalized to STAT3 and ERK1/2 expression, respectively.
-
Ruxolitinib purchased from MedChemExpress. Usage Cited in: J Hematol Oncol. 2021 Jun 24;14(1):97. [Abstract]
- Growth curves for DND-41, RPMI-8402 and LOUCY T-ALL cell lines. Growth medium is supplemented with DMSO, MRK-560 100 nM, Ruxolitinib 1 µM or both compounds.
-
Ruxolitinib purchased from MedChemExpress. Usage Cited in: Nat Commun. 2021 Aug 13;12(1):4917. [Abstract]
- The A3A mRNA level is monitored in MCF10A cells 16 h after treatment with 3p-hpRNA and JAK inhibitors (JAKi #1: 2 μM Pacritinib, JAKi #2: 2 μM Ruxolitinib).
-
Ruxolitinib purchased from MedChemExpress. Usage Cited in: Cancer Commun (Lond). 2021 Dec;41(12):1354-1372. [Abstract]
- The MAGE‐C3 overexpressing KYSE30 cells are treated with Ruxolitinib (2 μM, for 20 h.) and probed for STAT1 expression pSTAT1Tyr701. The pSTAT1Tyr701 expression levels are almost unchanged when exposure to Ruxolitinib in presence with IFN‐γ.
-
Ruxolitinib purchased from MedChemExpress. Usage Cited in: Cell Rep. 2020 Sep 15;32(11):108158. [Abstract]
- Cxcl10 and Ccl5 mRNA levels are analyzed in TNF-α (100 ng/mL)-stimulated BMDMs for 6 h, which are pretreated with notopterol (10 mM) in the presence or absence of ruxolitinib (10 μM) or SD1029 (10 μM) for 3 h.
-
Ruxolitinib purchased from MedChemExpress. Usage Cited in: Nat Med. 2018 Aug;24(8):1143-1150. [Abstract]
- Immunoblot of pSTAT1, STAT1 and β-actin levels in H69AR cells±200 ng/mL IFNg 10 min pulse followed by 24 h chase in media with DMSO, Ruxolitinib (100 nM) or MRT67307 (1 µM).
-
Ruxolitinib purchased from MedChemExpress. Usage Cited in: Cancer Discov. 2018 May;8(5):616-631. [Abstract]
- Analysis of PIM1 RNA and protein expression in HOXA9 positive patient derived xenograft (PDX) samples ex vivo after 1 μM Ruxolitinib over 6 hours.
-
Ruxolitinib purchased from MedChemExpress. Usage Cited in: Clin Cancer Res. 2018 Apr 15;24(8):1917-1931. [Abstract]
- Jak2 is inhibited by lentiviral expression of Jak2 shRNA or control shRNA in CWR22Pc and CWR22Rv1 cells. Alternatively, cells are treated with Jak2 inhibitors AZD1480 (0.8 μM) and Ruxolitinib (0.4 μM) (72 h), followed by Western blot analysis of Jak2 and active Stat5a/b.
-
Ruxolitinib purchased from MedChemExpress. Usage Cited in: JCI Insight. 2018 Sep 6;3(17). pii: 120750. [Abstract]
- A431 cells are then treated in full growth media with vehicle, CSA (50 ng/mL), Ruxolitinib (20 μM), or both Ruxolitinib and CSA for 36 hours.
-
Ruxolitinib purchased from MedChemExpress. Usage Cited in: J Biol Chem. 2015 Nov 27;290(48):29022-34. [Abstract]
- 106 autonomous Ba/F3 cells stably transduced with ALL-associated JAK3 mutant V674A or double mutant L857P/Y100A are treated with increasing concentration of Ruxolitinib (0–2 μM). Two hours after treatment, the cells are lysed and subjected to Western blot analysis. Phosphorylation of STAT5, JAK3, and JAK1 is detected using specific anti-pY694 STAT5, anti-pY980/81 JAK3, and anti-pY1034/35 JAK1 antibodies. Membranes are reprobed with anti-STAT5, anti-JAK3, anti-JAK1, and anti-β-actin an
-
Ruxolitinib purchased from MedChemExpress. Usage Cited in: Blood. 2013 Nov 21;122(22):3628-31. [Abstract]
- Ruxolitinib decreases spleen weight. Mice are sacrificed on day 21 or 24 to evaluate spleen size.